Literature DB >> 25180236

Altered phenotype and functionality of varicella zoster virus-specific cellular immunity in individuals with active infection.

David Schub1, Eva Janssen2, Sarah Leyking3, Urban Sester3, Gunter Assmann4, Pia Hennes5, Sigrun Smola6, Thomas Vogt2, Tilman Rohrer5, Martina Sester1, Tina Schmidt1.   

Abstract

BACKGROUND: Varicella zoster virus (VZV) establishes lifelong persistence and may reactivate in individuals with impaired immune function. To investigate immunologic correlates of protection and VZV reactivation, we characterized specific immunity in 207 nonsymptomatic immunocompetent and 132 immunocompromised individuals in comparison with patients with acute herpes zoster.
METHODS: VZV-specific CD4 T cells were quantified flow cytometrically after stimulation and characterized for expression of interferon-γ, interleukin 2, and tumor necrosis factor α and surface markers for differentiation (CD127) and anergy (cytotoxic T lymphocyte antigen 4 [CTLA-4] and programmed death [PD]-1). Immunoglobulin G and A levels were quantified using an enzyme-linked immunosorbent assay.
RESULTS: In healthy individuals, VZV-specific antibody and T-cell levels were age dependent, with the highest median VZV-specific CD4 T-cell frequencies of 0.108% (interquartile range, 0.121%) during adolescence. VZV-specific T-cell profiles were multifunctional with predominant expression of all 3 cytokines, CD127 positivity, and low expression of CTLA-4 and PD-1. Nonsymptomatic immunocompromised patients had similar VZV-specific immunologic properties except for lower T-cell frequencies (P<.001) and restricted cytokine expression. In contrast, significantly elevated antibody- and VZV-specific CD4 T-cell levels were found in patients with zoster. Their specific T cells showed a shift in cytokine expression toward interferon γ single positivity, an increase in CTLA-4 and PD-1, and a decrease in CD127 expression (all P<.001). This phenotype normalized after resolution of symptoms.
CONCLUSIONS: VZV-specific CD4-T cells in patients with zoster bear typical features of anergy. This phenotype is reversible and may serve as adjunct tool for monitoring VZV reactivations in high-risk patients.
© The Author 2014. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  T cells; VZV; cellular immunity; herpes zoster; shingles; varicella zoster virus

Mesh:

Substances:

Year:  2014        PMID: 25180236     DOI: 10.1093/infdis/jiu500

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  21 in total

1.  Immunogenicity of varicella zoster virus glycoprotein E DNA vaccine.

Authors:  Lidao Bao; Guomin Wei; Hongmei Gan; Xianhua Ren; Ruilian Ma; Y I Wang; Haijun Lv
Journal:  Exp Ther Med       Date:  2016-02-19       Impact factor: 2.447

2.  Test Is Also Helpful in Clinically Unclear Cases of Varicella Zoster.

Authors:  Bernd Maire
Journal:  Dtsch Arztebl Int       Date:  2020-03-06       Impact factor: 5.594

3.  Longitudinal analysis of varicella-zoster virus-specific antibodies in systemic lupus erythematosus: No association with subclinical viral reactivations or lupus disease activity.

Authors:  C Rondaan; C C van Leer; S van Assen; H Bootsma; K de Leeuw; S Arends; N A Bos; J Westra
Journal:  Lupus       Date:  2018-04-18       Impact factor: 2.911

4.  Pyruvate controls the checkpoint inhibitor PD-L1 and suppresses T cell immunity.

Authors:  Ryu Watanabe; Tsuyoshi Shirai; Hong Namkoong; Hui Zhang; Gerald J Berry; Barbara B Wallis; Benedikt Schaefgen; David G Harrison; Jennifer A Tremmel; John C Giacomini; Jörg J Goronzy; Cornelia M Weyand
Journal:  J Clin Invest       Date:  2017-06-12       Impact factor: 14.808

5.  Varicella-Zoster Virus-Specific Cellular Immune Responses to the Live Attenuated Zoster Vaccine in Young and Older Adults.

Authors:  Adriana Weinberg; Jennifer Canniff; Nadine Rouphael; Aneesh Mehta; Mark Mulligan; Jennifer A Whitaker; Myron J Levin
Journal:  J Immunol       Date:  2017-06-12       Impact factor: 5.422

6.  Insights into the pathogenesis of varicella viruses.

Authors:  Océane Sorel; Ilhem Messaoudi
Journal:  Curr Clin Microbiol Rep       Date:  2019-07-06

7.  Comparison of Lethal and Nonlethal Mouse Models of Orientia tsutsugamushi Infection Reveals T-Cell Population-Associated Cytokine Signatures Correlated with Lethality and Protection.

Authors:  Alison Luce-Fedrow; Suchismita Chattopadhyay; Teik-Chye Chan; Gregory Pearson; John B Patton; Allen L Richards
Journal:  Trop Med Infect Dis       Date:  2021-07-02

8.  Adaptive Immune Responses in a Multiple Sclerosis Patient with Acute Varicella-Zoster Virus Reactivation during Treatment with Fingolimod.

Authors:  Andrea Harrer; Peter Wipfler; Georg Pilz; Katrin Oppermann; Elisabeth Haschke-Becher; Shahrzad Afazel; Jörg Kraus; Eugen Trinka; Johann Sellner
Journal:  Int J Mol Sci       Date:  2015-09-10       Impact factor: 5.923

9.  Extensive CD4 and CD8 T Cell Cross-Reactivity between Alphaherpesviruses.

Authors:  Lichen Jing; Kerry J Laing; Lichun Dong; Ronnie M Russell; Russell S Barlow; Juergen G Haas; Meena S Ramchandani; Christine Johnston; Soren Buus; Alec J Redwood; Katie D White; Simon A Mallal; Elizabeth J Phillips; Christine M Posavad; Anna Wald; David M Koelle
Journal:  J Immunol       Date:  2016-01-25       Impact factor: 5.422

10.  Effector and Central Memory Poly-Functional CD4(+) and CD8(+) T Cells are Boosted upon ZOSTAVAX(®) Vaccination.

Authors:  Janet J Sei; Kara S Cox; Sheri A Dubey; Joseph M Antonello; David L Krah; Danilo R Casimiro; Kalpit A Vora
Journal:  Front Immunol       Date:  2015-10-29       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.